Improving the lives
of those suffering with neuroinflammatory diseases by providing more effective and safer medicines

Developed in Response to the Need for Change

GoodCap Pharmaceuticals, co-founded by a molecular biologist and innovative entrepreneurs, is dedicated to accelerating the recovery process for individuals struggling with disorders triggered by neuroinflammation.

Lead Candidate

GoodCap’s lead drug candidate, GCAP001, combines two classes of molecules that when at specific and proprietary ratios, greatly reduce key inflammatory biomarkers directly associated with the broad symptomology of psychiatric and neurodegenerative disorders. GoodCap’s focus is on its beachhead indication of PTSD.

Improving the lives of those suffering with neuroinflammatory diseases by providing more effective and safer medicines

Improving the lives
of those suffering with neuroinflammatory diseases by providing more effective and safer medicines